Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
A. Hosokawa, Satoshi Yuki, Yasuyuki Kawamoto, Takayuki Ando, Osamu Muto, Michio Nakamura, Takashi Kato, Ichiro Iwanaga, Kazuteru Hatanaka, Yasushi Tsuji, Akinori Sato, K. Eto, Kouichi Furukawa, Hiroyuki Okuda, Hideo Hayashi, Kei Fujikawa, Masatoshi Kudo, Takuya Honda, Yuh Sakata, Yoshito Komatsu (2015). 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.23.
Article38 days ago2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV
Hiroshi Nakatsumi, Satoshi Yuki, Yasuyuki Kawamoto, Toshiya Muranaka, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, Kojiro Eto, Masatoshi Kudo, Seiya Kato, Hiroyuki Okuda, Susumu Sogabe, Kencho Miyashita, Yuh Sakata, Naoya Sakamoto, Yoshihiko Komatsu (2015). 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31014-0.
Article38 days ago2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy
Y. Kobayashi, Satoshi Yuki, Yasuyuki Kawamoto, K Sawada, T. Miyagishima, Nobuyuki Ehira, Ichiro Iwanaga, Hiroyuki Okuda, M. Tateyama, Yasushi Tsuji, Kazuteru Hatanaka, Michio Nakamura, Masatoshi Kudo, H. Fukushima, T. Tagaki, Hiroyuki Hisai, Masahiko Koike, R. Abe, Yasushi Sakata, Yoshimichi Komatsu (2015). 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31016-4.
Article38 days ago2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV
Hiroshi Nakatsumi, Satoshi Yuki, Yasuyuki Kawamoto, Toshiya Muranaka, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, Kojiro Eto, Masatoshi Kudo, Seiya Kato, Hiroyuki Okuda, Susumu Sogabe, Kencho Miyashita, Yuh Sakata, Naoya Sakamoto, Yoshihiko Komatsu, Masatoshi Kudo (2015). 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31014-0.
Article38 days ago